Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00103038 · ClinicalTrials.gov registry record · NA
Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases
A NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 155
- Enrollment target
- 1
- Study location
NCT00103038 is a NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 155 participants, above the 84-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (85% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00103038, a NA study of Metastatic Malignant Neoplasm in the Brain and Malignant Glioma, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 155 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help find and diagnose brain tumors and find out how far the disease has spread. The contrast imaging agent ferumoxytol non-stoichiometric magnetite consists of small iron particles taken by the blood stream to the brain and to the area of the tumor. It may help visualize the blood flow going through the tumor better than the standard substance gadolinium-based contrast agent.
Conditions Studied
Interventions
- DRUG Ferumoxytol
- DRUG Gadolinium
- PROCEDURE Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- PROCEDURE 3 Tesla Magnetic Resonance Imaging
- PROCEDURE Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2004-06-04 |
| Est. Completion | 2016-06-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00103038
The ClinicalTrials.gov registry entry for NCT00103038 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 84-participant average among 43 other Metastatic Malignant Neoplasm in the Brain trials with a reported enrollment target (85% higher). The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Metastatic Malignant Neoplasm in the Brain appearing as the primary indexed condition, and to 5 interventions - of which Ferumoxytol is the first listed.
NCT00103038 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT00103038 about?
NCT00103038 is a clinical study titled "Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases". This clinical trial studies magnetic resonance imaging (MRI) using a contrast imaging agent ferumoxytol (ferumoxytol non-stoichiometric magnetite) in improving viewing tumors in patients with high-grade brain tumors or cancer that has spread to the brain. Diagnostic procedures, such as MRI, may help...
What is the current status of trial NCT00103038?
This trial is currently completed. It is a NA study. The enrollment target is 155 participants. The study started on 2004-06-04. Estimated completion is 2016-06-10.
What conditions does trial NCT00103038 study?
This clinical trial studies the following conditions: Metastatic Malignant Neoplasm in the Brain, Malignant Glioma, Central Nervous System Lymphoma.
What interventions are being tested in trial NCT00103038?
The interventions under investigation include: Ferumoxytol (DRUG), Gadolinium (DRUG), Dynamic Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE), 3 Tesla Magnetic Resonance Imaging (PROCEDURE), Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT00103038?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00103038 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Malignant Neoplasm in the Brain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
RECRUITING · NA
-
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
RECRUITING · NA
-
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
RECRUITING · NA
-
Feasibility of Intraoperative Microdialysis During Neurosurgery for Central Nervous System Malignancies
RECRUITING · NA
-
nTMS in Planning Stereotactic Radiosurgery in Patients With Brain Metastases in the Motor Cortex
ACTIVE NOT RECRUITING · NA
-
Mind-Body Intervention in Glioma Couples
ACTIVE NOT RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.